Pricing & Access· July 5, 2026 · 16 min read
Section
Pricing & Access
Coverage, formulary strategy, prior authorization, patient assistance, IRA negotiation, and gross-to-net pressure.
142 articles · Last updated
Pricing & Access· July 5, 2026 · 17 min read
Winrevair (sotatercept) access landscape: PAH cost and coverage after ZENITH
Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage
Pricing & Access· June 30, 2026 · 18 min read
China's 2026 Dual-Track Drug Catalog: Reading NHSA Preliminary Numbers
By Ran Chen#China#Market Access#Drug Pricing
Pricing & Access· June 28, 2026 · 21 min read
Casgevy Access Guide: CMS CGT Model, State Medicaid Criteria, and the ATC Network
By Ran Chen#Medicaid#Prior Authorization#Gene Therapy
Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars
Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics
Pricing & Access· June 24, 2026 · 26 min read
Pfizer Portfolio Dossier: Patent Cliffs, Shortages, and Recalls
By Ran Chen#Orange Book#Purple Book#FDA Approval